

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
None identified	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
N/A	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
N/A	

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Issue date: October 2023

Approved by Associate Director (name): ...Linda Landells....

Date: ...18 October 2023.....